265 related articles for article (PubMed ID: 25763728)
21. PET/CT and MR imaging in myeloma.
Mulligan ME; Badros AZ
Skeletal Radiol; 2007 Jan; 36(1):5-16. PubMed ID: 16915386
[TBL] [Abstract][Full Text] [Related]
22. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X
Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.
Siontis B; Kumar S; Dispenzieri A; Drake MT; Lacy MQ; Buadi F; Dingli D; Kapoor P; Gonsalves W; Gertz MA; Rajkumar SV
Blood Cancer J; 2015 Oct; 5(10):e364. PubMed ID: 26495861
[TBL] [Abstract][Full Text] [Related]
24. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
25. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
26. [Modern imaging techniques in patients with multiple myeloma].
Bannas P; Kröger N; Adam G; Derlin T
Rofo; 2013 Jan; 185(1):26-33. PubMed ID: 23196838
[TBL] [Abstract][Full Text] [Related]
27. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
[TBL] [Abstract][Full Text] [Related]
28. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.
Caers J; Withofs N; Hillengass J; Simoni P; Zamagni E; Hustinx R; Beguin Y
Haematologica; 2014 Apr; 99(4):629-37. PubMed ID: 24688111
[TBL] [Abstract][Full Text] [Related]
29. Imaging patients with myeloma.
Winterbottom AP; Shaw AS
Clin Radiol; 2009 Jan; 64(1):1-11. PubMed ID: 19070692
[TBL] [Abstract][Full Text] [Related]
30. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
31. The Critical Role of Imaging in the Management of Multiple Myeloma.
Raza S; Leng S; Lentzsch S
Curr Hematol Malig Rep; 2017 Jun; 12(3):168-175. PubMed ID: 28317080
[TBL] [Abstract][Full Text] [Related]
32. Benefits of individual imaging methods for diagnosis and monitoring of activity of multiple myeloma.
Vanicek J; Szturz P; Rehak Z; Kianicka B; Bulik M
Klin Onkol; 2012; 25(3):166-72. PubMed ID: 22724564
[TBL] [Abstract][Full Text] [Related]
33. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
34. [Radiological diagnostics of multiple myeloma].
D'Anastasi M; Grandl S; Reiser MF; Baur-Melnyk A
Radiologe; 2014 Jun; 54(6):556-63. PubMed ID: 24927658
[TBL] [Abstract][Full Text] [Related]
35. PET/MR Imaging of Multiple Myeloma.
Shah SN; Oldan JD
Magn Reson Imaging Clin N Am; 2017 May; 25(2):351-365. PubMed ID: 28390534
[TBL] [Abstract][Full Text] [Related]
36. 68Ga-DOTANOC somatostatin receptor PET-CT imaging in multiple myeloma.
Sharma P; Dhull VS; Suman S; Bal C; Malhotra A; Kumar R
Clin Nucl Med; 2014 Apr; 39(4):374-5. PubMed ID: 23640227
[TBL] [Abstract][Full Text] [Related]
37. Mass-forming extramedullary hematopoiesis in multiple myeloma: 18F-FDG PET/CT is useful in excluding extramedullary myeloma involvement.
Seo M; Kim H; Jo JC; Choi Y; Cha HJ; Lim JH; Park SH
Tumori; 2016 Nov; 102(Suppl. 2):116-118. PubMed ID: 26429647
[TBL] [Abstract][Full Text] [Related]
38. Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques.
Rubini G; Niccoli-Asabella A; Ferrari C; Racanelli V; Maggialetti N; Dammacco F
Crit Rev Oncol Hematol; 2016 May; 101():169-83. PubMed ID: 26997302
[TBL] [Abstract][Full Text] [Related]
39. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.
Mesguich C; Zanotti-Fregonara P; Hindié E
Theranostics; 2016; 6(2):287-90. PubMed ID: 26877786
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Advances in Multiple Myeloma.
Barley K; Chari A
Curr Hematol Malig Rep; 2016 Apr; 11(2):111-7. PubMed ID: 26922745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
